Status:
NOT_YET_RECRUITING
Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy
Lead Sponsor:
Medical College of Wisconsin
Conditions:
Clostridioides Difficile Infection
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
The goal of this clinical trial is to determine whether Ursodeoxycholic Acid (UDCA) can help prevent recurrence of Clostridioides difficile (C. diff) colitis when used along with standard antibiotic t...
Detailed Description
Prevention of Recurrence of Clostridioides Difficile Colitis with Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy Paraj D. Patel M.D, Daniel J. Stein, M.D, Helmut V. Ammon, MD This ...
Eligibility Criteria
Inclusion
- Eligible patients: C. diff. toxin +ve patients \> 18 years with one or more risk factors for recurrence \[6,7\] requiring standard treatment with Flagyl, Vancomycin or fidaxomicin.
Exclusion
- Life expectancy \< 6 months; fulminant colitis; ileus; decompensated liver disease; pregnancy and lactating females; Inability to give informed consent.
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06884748
Start Date
December 1 2025
End Date
May 1 2028
Last Update
October 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Daniel Stein
Milwaukee, Wisconsin, United States, 53226